FDA approves broad‑spectrum parasiticide for cats

With four applications per year, Felpreva (emodepside, praziquantel, and tigolaner topical solution) reportedly treats and prevents fleas and treats and controls black-legged ticks for 12 weeks, and lone star ticks for eight weeks, in feline patients.

Vetoquinol USA, Inc., announces that Felpreva (emodepside, praziquantel, and tigolaner topical solution) has received approval from the U.S. Food & Drug Administration (FDA).

The prescription-only broad-spectrum parasiticide for cats combines three active ingredients: emodepside to treat roundworms; praziquantel to treat tapeworms; and tigolaner to control fleas, ticks, and mites. It reportedly treats and prevents fleas and treats and controls black-legged ticks for 12 weeks; treats and controls lone star ticks for eight weeks in feline patients at least six months of age, weighing at least 2.2 lb.

Fluffy red and white cat, street cat sits, Itchy cat
Bigstockphoto

"We are excited to bring Felpreva to U.S. veterinarians and cat owners," says Michael Maginnis, country manager, Vetoquinol USA. "Felpreva takes the complexity out of parasite control for both veterinarians and cat owners by providing a straightforward solution: Fewer applications with broad-spectrum treatment and control."

Felpreva will be available for purchase from distributors by 2027. For more information, visit the Vetoquinol USA website.

Comments
Post a Comment

Comments